AR080228A1 - Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion - Google Patents
Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacionInfo
- Publication number
- AR080228A1 AR080228A1 ARP110100517A AR080228A1 AR 080228 A1 AR080228 A1 AR 080228A1 AR P110100517 A ARP110100517 A AR P110100517A AR 080228 A1 AR080228 A1 AR 080228A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally
- hydrogen
- ring
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los compuestos son inhibidores de la proteína de transferencia de éster de colesterol (CETP) por lo tanto, son adecuados para el tratamiento y prevencion de enfermedades que pueden influenciarse por la inhibicion de esta enzima. Composicion farmacéutica. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en la que R1 es un grupo arilo o heteroarilo mono- o bicíclico, de 5 a 10 miembros, donde el heteroarilo contiene de 1 a 4 heteroátomos seleccionados entre el grupo que consiste en N, O y S, y donde el arilo o el heteroarilo pueden estar opcionalmente sustituidos con R9, R10 y/o R11, donde R9 es hidrogeno, halogeno, ciano, alquilo C1-4, alquenilo C2-4, cicloalquilo C3-6, alcoxi C1-4, alquilo C1-4 completa o parcialmente sustituido con fluor, alcoxi C1-4 completa o parcialmente sustituido con fluor, pentafluorosulfanilo, ciano-alquilo C1-4, alquil C1-2-cicloalquilo C3-6, ciano-cicloalquilo C3-6, alcoxi C1-2-alquilo C1-4, hidroxialquilo C1-4 o 3-(alquil C1-2)-oxetan-3-ilo; R10 es hidrogeno, halogeno, ciano, alquilo C1-4, alquenilo C2-4, cicloalquilo C3-6, alcoxi C1-4, alquilo C1-4 completa o parcialmente sustituido con fluor, alcoxi C1-4 completa o parcialmente sustituido con fluor, ciano-alquilo C1-4, metil-cicloalquilo C3-6, ciano-cicloalquilo C3-6, metoxi-alquilo C1-4, hidroxi-alquilo C1-4 o 3-(alquil C1-2)-oxetan-3-ilo; R11 es hidrogeno o halogeno; o R9 y R10 juntos y con la inclusion de los átomos de carbono a los que están unidos, forman un anillo de cicloalcano C5-6 en el que un grupo metileno puede estar opcionalmente reemplazado por oxígeno, donde el anillo, para el caso de un sistema de anillo de 6 miembros, puede contener opcionalmente un doble enlace, y/o donde el anillo puede estar opcionalmente mono- o disustituido con metilo, donde, para el caso en el que los dos grupos metilo están conectados al mismo carbono, los grupos metilo, junto con el carbono al que están conectados, pueden formar opcionalmente un anillo de ciclopropilo; R2 es alquilo C1-6, perfluoroalquilo C1-3, alcoxi C1-4-alquilo C1-4 o cicloalquilo C4-7, donde el cicloalquilo C4-7 puede estar opcionalmente mono- o disustituido con fluor, hidroxi, metoxi y/o alquilo C1-2 y donde, para el caso de sistemas de cicloalquilo C5-7, un grupo metileno puede estar opcionalmente reemplazado por oxígeno; R3 es hidrogeno o alquilo C1-4; R4 es hidrogeno o alquilo C1-4; o R3 y R4 juntos y con inclusion del átomo de carbono al que están unidos, forman un anillo de cicloalcano C3-7; R5 es hidrogeno o alquilo C1-4; R6 es alquilo C1-4; R7 es hidrogeno o alquilo C1-4; o R6 y R7 juntos y con inclusion del átomo de carbono al que están unidos, forman un anillo de cicloalcano C5-7 en el que un grupo metileno puede estar opcionalmente reemplazado por oxígeno, donde el anillo puede contener opcionalmente un doble enlace, y/o donde el anillo puede estar opcionalmente mono o disustituido con fluor, hidroxilo, alcoxi C1-2 y/o alquilo C1-2; R8 es hidrogeno, acetoxi, propioniloxi, metoxi o hidroxi; sus tautomeros, sus estereoisomeros, las mezclas de los mismos y las sales de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10154086 | 2010-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080228A1 true AR080228A1 (es) | 2012-03-21 |
Family
ID=43877277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100517 AR080228A1 (es) | 2010-02-19 | 2011-02-18 | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion |
Country Status (22)
Country | Link |
---|---|
US (2) | US20120053197A1 (es) |
EP (1) | EP2536733B1 (es) |
JP (1) | JP5780528B2 (es) |
KR (1) | KR20130000379A (es) |
CN (1) | CN102869667A (es) |
AP (1) | AP2012006390A0 (es) |
AR (1) | AR080228A1 (es) |
AU (1) | AU2011217206A1 (es) |
BR (1) | BR112012020591A2 (es) |
CA (1) | CA2790643A1 (es) |
CL (1) | CL2012002035A1 (es) |
CO (1) | CO6592112A2 (es) |
EA (1) | EA201201160A1 (es) |
EC (1) | ECSP12012157A (es) |
MA (1) | MA34007B1 (es) |
MX (1) | MX2012009149A (es) |
PE (1) | PE20121743A1 (es) |
SG (1) | SG183321A1 (es) |
TN (1) | TN2012000418A1 (es) |
TW (1) | TW201139445A (es) |
UY (1) | UY33229A (es) |
WO (1) | WO2011101424A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009221179A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
SG183321A1 (en) | 2010-02-19 | 2012-09-27 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130053404A1 (en) * | 2011-02-17 | 2013-02-28 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
WO2013024130A1 (en) * | 2011-08-17 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
WO2013024149A1 (en) * | 2011-08-18 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Crystalline forms of octahydro-3h-spiro [furo [3, 4-c] quinoline -1, 4 '-pyran] -9-ol |
US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
CN103882766B (zh) * | 2014-03-21 | 2015-10-28 | 湖南中烟工业有限责任公司 | 一种除去包装卡纸中酮类物质的除酮添加剂及其应用 |
CN103866646B (zh) * | 2014-03-21 | 2015-10-28 | 湖南中烟工业有限责任公司 | 一种生产无酮转移卡纸的工艺 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4798619A (en) | 1980-06-02 | 1989-01-17 | American Cyanamid Co. | 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents |
US4475407A (en) | 1982-12-27 | 1984-10-09 | Brunswick Corporation | Temperature compensated flow sensor |
CH664578A5 (de) * | 1985-01-15 | 1988-03-15 | Ciba Geigy Ag | Ringsubstituierte 4-azaphthalide. |
WO1990002129A1 (en) | 1988-08-16 | 1990-03-08 | The Upjohn Company | Bivalent ligands effective for blocking acat enzyme |
NZ319596A (en) | 1995-09-29 | 1999-09-29 | Glaxo Wellcome Spa | 4-phenylcarbamoylmethylene-1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
HUP0004935A3 (en) | 1997-09-04 | 2001-12-28 | Basf Ag | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
DE69935992T4 (de) | 1998-09-25 | 2008-05-29 | Monsanto Co., Chicago | Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
US6723752B2 (en) | 1999-09-23 | 2004-04-20 | Pharmacia Corporation | (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6458849B1 (en) | 1999-09-23 | 2002-10-01 | G.D. Searle & Co. | use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity |
US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
DE10238243A1 (de) * | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1737811B1 (en) | 2004-04-13 | 2016-08-10 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
DE102004060997A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Chemische Verbindung und ihre Verwendung |
BRPI0519566A2 (pt) | 2004-12-18 | 2009-01-27 | Bayer Healthcare Ag | derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp |
BRPI0519602A2 (pt) | 2004-12-18 | 2009-02-25 | Bayer Healthcare Ag | derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento |
JP2008201760A (ja) * | 2007-02-22 | 2008-09-04 | Tokyo Univ Of Agriculture & Technology | 光学活性スピロ化合物及びその製造方法 |
AU2009221179A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
SG183321A1 (en) | 2010-02-19 | 2012-09-27 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130053404A1 (en) | 2011-02-17 | 2013-02-28 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
WO2013024130A1 (en) | 2011-08-17 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
WO2013024149A1 (en) | 2011-08-18 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Crystalline forms of octahydro-3h-spiro [furo [3, 4-c] quinoline -1, 4 '-pyran] -9-ol |
-
2011
- 2011-02-17 SG SG2012060273A patent/SG183321A1/en unknown
- 2011-02-17 WO PCT/EP2011/052376 patent/WO2011101424A1/en active Application Filing
- 2011-02-17 MX MX2012009149A patent/MX2012009149A/es not_active Application Discontinuation
- 2011-02-17 KR KR20127021473A patent/KR20130000379A/ko not_active Application Discontinuation
- 2011-02-17 US US13/029,690 patent/US20120053197A1/en not_active Abandoned
- 2011-02-17 UY UY33229A patent/UY33229A/es not_active Application Discontinuation
- 2011-02-17 EA EA201201160A patent/EA201201160A1/ru unknown
- 2011-02-17 JP JP2012553323A patent/JP5780528B2/ja active Active
- 2011-02-17 AP AP2012006390A patent/AP2012006390A0/xx unknown
- 2011-02-17 MA MA35152A patent/MA34007B1/fr unknown
- 2011-02-17 PE PE2012001247A patent/PE20121743A1/es not_active Application Discontinuation
- 2011-02-17 CA CA 2790643 patent/CA2790643A1/en not_active Abandoned
- 2011-02-17 BR BR112012020591A patent/BR112012020591A2/pt not_active IP Right Cessation
- 2011-02-17 CN CN2011800198873A patent/CN102869667A/zh active Pending
- 2011-02-17 EP EP20110704227 patent/EP2536733B1/en active Active
- 2011-02-17 AU AU2011217206A patent/AU2011217206A1/en not_active Abandoned
- 2011-02-17 US US13/029,697 patent/US9029544B2/en active Active
- 2011-02-18 TW TW100105535A patent/TW201139445A/zh unknown
- 2011-02-18 AR ARP110100517 patent/AR080228A1/es unknown
-
2012
- 2012-07-20 CL CL2012002035A patent/CL2012002035A1/es unknown
- 2012-08-16 TN TNP2012000418A patent/TN2012000418A1/en unknown
- 2012-08-21 CO CO12141229A patent/CO6592112A2/es unknown
- 2012-09-14 EC ECSP12012157 patent/ECSP12012157A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011101424A1 (en) | 2011-08-25 |
ECSP12012157A (es) | 2012-10-30 |
US20120046304A1 (en) | 2012-02-23 |
BR112012020591A2 (pt) | 2017-10-10 |
EA201201160A1 (ru) | 2013-04-30 |
US20120053197A1 (en) | 2012-03-01 |
AU2011217206A1 (en) | 2012-08-02 |
CN102869667A (zh) | 2013-01-09 |
SG183321A1 (en) | 2012-09-27 |
PE20121743A1 (es) | 2012-12-22 |
CO6592112A2 (es) | 2013-01-02 |
US9029544B2 (en) | 2015-05-12 |
MX2012009149A (es) | 2012-09-28 |
CA2790643A1 (en) | 2011-08-25 |
MA34007B1 (fr) | 2013-02-01 |
AP2012006390A0 (en) | 2012-08-31 |
KR20130000379A (ko) | 2013-01-02 |
EP2536733B1 (en) | 2014-11-26 |
TN2012000418A1 (en) | 2014-01-30 |
TW201139445A (en) | 2011-11-16 |
JP2013519709A (ja) | 2013-05-30 |
EP2536733A1 (en) | 2012-12-26 |
JP5780528B2 (ja) | 2015-09-16 |
UY33229A (es) | 2011-09-30 |
CL2012002035A1 (es) | 2013-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20160588A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
ECSP088891A (es) | Derivados bicíclicos como inhibidores de cetp | |
AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
AR093740A1 (es) | Amidas como inhibidores de pim | |
UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
AR061083A1 (es) | Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen | |
AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
ES2685568T3 (es) | Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa | |
ECSP11011011A (es) | Derivados de acido 1-amino-2-ciclobutiletilborónico | |
AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
UY29070A1 (es) | Enantiómeros de heterocíclicos fusionados y sus usos | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR084637A1 (es) | Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia | |
AR067648A1 (es) | Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |